# ğŸ¥ AYESHA KIANI - CLINICAL SUMMARY & MONITORING PLAN

**Patient:** AK  
**DOB:** 6/25/1985 (Age 40)  
**MRN:** 1011021118 / 68741392  
**Last Updated:** November 2025

---

## ğŸ“‹ DIAGNOSIS SUMMARY

### Confirmed Diagnosis: **HIGH-GRADE SEROUS OVARIAN/TUBAL CARCINOMA (HGSOC)**

| Finding | Source | Date |
|---------|--------|------|
| Metastatic adenocarcinoma, Mullerian primary | Cytology (pleural fluid) | Nov 2025 |
| Extensive carcinomatosis | PET-CT | Nov 2025 |
| TP53 mutant (p53 strong diffuse staining) | IHC | Nov 2025 |
| ER positive (60%) | IHC | Nov 2025 |
| PR negative (0%) | IHC | Nov 2025 |
| **MBD4 Germline c.1293delA (Homozygous)** â­ | MBD4 Analysis (Ambry) | Jan 2025 |
| **Germline BRCA1/2 Negative** | Ambry 38-gene panel | June 2023 |

### Stage: **IVB** (FIGO)
- Bilateral pleural effusions with metastatic deposits
- Extensive abdominopelvic carcinomatosis
- Omental caking
- Nodal metastases (cervical, thoracic, abdominopelvic)

---

## â­ CRITICAL GENETIC FINDING: MBD4 + TP53 "DOUBLE HIT"

### MBD4 Germline Mutation

| Field | Value |
|-------|-------|
| **Gene** | MBD4 (Methyl-CpG Binding Domain Protein 4) |
| **Variant** | c.1293delA (frameshift deletion) |
| **Protein Effect** | p.K431Nfs*54 (truncation) |
| **Zygosity** | **HOMOZYGOUS** (both alleles affected) |
| **Classification** | Loss-of-function |
| **Pathway Affected** | Base Excision Repair (BER) |

### TP53 Somatic Mutation

| Field | Value |
|-------|-------|
| **Gene** | TP53 |
| **Evidence** | p53 strong diffuse staining (IHC) = mutant-type |
| **Likely Variant** | R175H, R248Q, or R273H (HGSOC hotspots) |
| **Classification** | Loss-of-function / Dominant-negative |
| **Pathway Affected** | Cell cycle checkpoint, apoptosis |

### What This Means

```
MBD4 Homozygous Loss â†’ BER Pathway Deficiency â†’ Cannot repair base damage
        +
TP53 Somatic Mutation â†’ Checkpoint Bypass â†’ Cannot stop damaged cells

        = SYNTHETIC LETHALITY OPPORTUNITY
```

**Clinical Implications:**
1. **HIGH SENSITIVITY to PARP inhibitors** (olaparib, niraparib, rucaparib)
2. **HIGH SENSITIVITY to platinum chemotherapy** (carboplatin)
3. **Potential for ATR/CHK1/WEE1 inhibitors** (clinical trials)
4. **May have elevated TMB** (BER deficiency â†’ increased mutations)

---

## ğŸ”¬ WHAT WE HAVE (Current Tests)

### âœ… 1. Germline Genomics (Ambry CustomNext - June 2023)

| Result | Details |
|--------|---------|
| **NEGATIVE** | No pathogenic mutations detected |
| Genes Tested | 38 genes including BRCA1, BRCA2, ATM, PALB2, RAD51C, RAD51D, CHEK2, NF1, TP53, MSH2, MLH1 |
| VUS | None |
| Deletions/Duplications | None |

**Implication:** This is a **SPORADIC** cancer. Germline testing does NOT rule out somatic BRCA or HRD.

---

### âœ… 2. Cytology/Pathology (November 2025)

**Specimen:** Right pleural fluid (1400cc bloody fluid)

**Immunohistochemistry Panel:**

| Marker | Result | Interpretation |
|--------|--------|----------------|
| PAX8 | + | Mullerian origin confirmed |
| WT1 | + | Serous differentiation |
| CK7 | + | Epithelial origin |
| claudin4 | + | Epithelial |
| MOC31 | + | Carcinoma |
| p53 | Strong diffuse + | **TP53 MUTANT** |
| p16 | Strong diffuse + | High-grade serous |
| ER | 60% + | Hormone receptor positive |
| PR | 0% | Negative |
| calretinin | - | Not mesothelial |
| TTF1 | - | Not lung primary |
| GATA3 | - | Not breast/urothelial |
| CK20 | - | Not GI primary |

**Diagnosis:** High-grade serous carcinoma of Mullerian (ovarian/tubal) primary

---

### âœ… 3. PET-CT (November 2025)

**Key Findings:**

| Location | Finding | SUV max |
|----------|---------|---------|
| Right lower quadrant | Largest tumor mass (8 cm) | **15** |
| Uterine cervix | FDG-avid focus | 11 |
| Right axillary LN | 1.8 x 1.1 cm | 9.5 |
| Abdominopelvic nodes | Innumerable, up to 2 cm | 8-10 |
| Pleural deposits | Bilateral | 6-7 |
| Endometrium | FDG-avid | 6.2 |
| Left arm soft tissue | 3.0 x 2.5 cm lesion | 4.2 |

**Disease Burden:**
- âœ“ Extensive carcinomatosis
- âœ“ Moderate volume ascites
- âœ“ Bilateral pleural effusions (large)
- âœ“ Omental caking
- âœ“ Left adnexal cystic lesion with FDG-avid periphery

---

### âœ… 4. CT Abdomen/Pelvis (February 2024 - Historical)

- Status post total colectomy (01/02/2024) for tubular adenomas
- Left ovarian cysts: 5.2 cm + 4.4 cm
- No bowel obstruction

---

## âœ… TESTS WE HAVE / âŒ TESTS STILL NEEDED

### âœ… ALREADY COMPLETED

| Test | Result | Impact |
|------|--------|--------|
| **Germline Panel (38 genes)** | BRCA1/2 NEGATIVE | Not hereditary BRCA |
| **MBD4 Germline Analysis** | c.1293delA HOMOZYGOUS â­ | BER deficiency â†’ HIGH PARP sensitivity |
| **Cytology/IHC** | TP53 mutant, ER+, PR- | Confirms HGSOC, TP53 loss |
| **PET-CT** | Extensive carcinomatosis | Stage IVB confirmed |

### ğŸ”´ MUST ORDER IMMEDIATELY

| Test | Why Critical | Impact on Treatment |
|------|--------------|---------------------|
| **CA-125 Baseline** â­ | No baseline exists! | Cannot track treatment response |
| **HRD Score** (Myriad myChoice) | MBD4 + TP53 suggests high HRD | Confirms PARP eligibility (likely HRD+) |
| **MSI/dMMR Testing** | MBD4 loss may cause MSI | If MSI-H â†’ eligible for immunotherapy |
| **TMB Estimation** | BER deficiency â†’ likely elevated | If TMB-H â†’ IO combination |

### ğŸŸ¢ GOOD NEWS: MBD4 CHANGES EVERYTHING

With **MBD4 homozygous + TP53 mutation**:
- âœ… **PARP inhibitors: STRONGLY INDICATED** (synthetic lethality)
- âœ… **Platinum: HIGH SENSITIVITY expected** (DNA crosslinks can't be repaired)
- âœ… **HRD score likely HIGH** (even without BRCA1/2, BER deficiency causes HRD)
- âš ï¸ **MSI may be elevated** (MBD4 loss â†’ microsatellite instability)

### ğŸŸ¡ RECOMMENDED ADDITIONAL TESTS

| Test | Why Useful | Timing |
|------|------------|--------|
| **Somatic Tumor Sequencing** | Confirm TP53 variant, check other mutations | Before maintenance |
| **ctDNA/Liquid Biopsy** | MRD monitoring, resistance detection | Baseline + serial |
| **ATR/CHK1/WEE1 biomarkers** | Clinical trial eligibility | If PARP fails |

---

## ğŸ“Š MONITORING SCHEDULE

### Phase 1: Pre-Treatment (NOW)

```
Week 0-1:
â”œâ”€â”€ CA-125 baseline â­ URGENT
â”œâ”€â”€ Somatic tumor sequencing â­ URGENT
â”œâ”€â”€ HRD score request â­ URGENT
â”œâ”€â”€ CBC, CMP, LFTs
â”œâ”€â”€ MSI/dMMR testing
â””â”€â”€ Albumin, pre-albumin (nutritional)
```

### Phase 2: During Neoadjuvant Chemotherapy

**Expected Regimen:** Carboplatin AUC5 + Paclitaxel q3w Ã— 3-4 cycles

```
Every Cycle (q3 weeks):
â”œâ”€â”€ CA-125 â­
â”œâ”€â”€ CBC with differential
â”œâ”€â”€ CMP (creatinine, electrolytes)
â””â”€â”€ Clinical assessment

After Cycle 3:
â”œâ”€â”€ CT Chest/Abdomen/Pelvis â­
â”œâ”€â”€ Response assessment (RECIST)
â””â”€â”€ Surgical planning if responding
```

### Phase 3: Interval Debulking Surgery (IDS)

```
Pre-Surgery:
â”œâ”€â”€ CT imaging
â”œâ”€â”€ CA-125
â””â”€â”€ Nutritional optimization

Post-Surgery:
â”œâ”€â”€ Pathology: Response assessment (CRS score)
â”œâ”€â”€ Residual disease documentation
â””â”€â”€ Discuss maintenance therapy
```

### Phase 4: Adjuvant Chemotherapy + Maintenance

```
Adjuvant Chemo (3-4 more cycles):
â”œâ”€â”€ CA-125 each cycle
â”œâ”€â”€ CBC, CMP each cycle
â””â”€â”€ CT after completion

Maintenance Phase (if HRD+):
â”œâ”€â”€ PARP inhibitor (olaparib/niraparib)
â”œâ”€â”€ CA-125 monthly Ã— 6, then q3 months
â”œâ”€â”€ CT q3-4 months Ã— 2 years
â””â”€â”€ ctDNA if available
```

### Phase 5: Surveillance (Post-Maintenance)

```
Year 1-2:
â”œâ”€â”€ CA-125 every 3 months
â”œâ”€â”€ CT every 3-4 months
â”œâ”€â”€ Clinical exam every 3 months
â””â”€â”€ ctDNA annually if baseline available

Year 3-5:
â”œâ”€â”€ CA-125 every 6 months
â”œâ”€â”€ CT every 6 months
â””â”€â”€ Clinical exam every 6 months
```

---

## ğŸ¯ TREATMENT PATHWAY DECISION TREE

```
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  SOMATIC TESTING    â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                               â”‚
           â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
           â–¼                   â–¼                   â–¼
    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚   HRD+       â”‚   â”‚   HRD-       â”‚   â”‚   BRCA+      â”‚
    â”‚  (score â‰¥42) â”‚   â”‚  (score <42) â”‚   â”‚  (somatic)   â”‚
    â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”˜
           â”‚                  â”‚                  â”‚
           â–¼                  â–¼                  â–¼
    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚ PARP + Bev   â”‚   â”‚ Bev alone or â”‚   â”‚ PARP mono-   â”‚
    â”‚ maintenance  â”‚   â”‚ observation  â”‚   â”‚ therapy      â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ¯ TREATMENT RECOMMENDATIONS (Based on MBD4 + TP53)

### Expected Treatment Pathway

```
NEOADJUVANT CHEMOTHERAPY
â”œâ”€â”€ Carboplatin AUC5 + Paclitaxel q3w Ã— 3-4 cycles
â”œâ”€â”€ Expected: HIGH RESPONSE (MBD4 + TP53 = platinum sensitive)
â””â”€â”€ Monitor: CA-125 every cycle

        â†“ If response â†“

INTERVAL DEBULKING SURGERY (IDS)
â”œâ”€â”€ Goal: R0 resection (no visible residual disease)
â”œâ”€â”€ Pathology: Assess chemotherapy response (CRS score)
â””â”€â”€ Document residual disease

        â†“

ADJUVANT CHEMOTHERAPY
â”œâ”€â”€ 3-4 additional cycles carboplatin/paclitaxel
â””â”€â”€ Complete total of 6-8 cycles

        â†“

MAINTENANCE THERAPY â­ CRITICAL FOR AYESHA
â”œâ”€â”€ PARP INHIBITOR (Olaparib or Niraparib) â­ STRONGLY INDICATED
â”‚   â””â”€â”€ Rationale: MBD4 loss + TP53 = synthetic lethality with PARP
â”œâ”€â”€ Â± Bevacizumab (if high residual disease)
â””â”€â”€ Duration: 2-3 years or until progression
```

### Drug Priority Based on MBD4 + TP53

| Drug Class | Priority | Rationale |
|------------|----------|-----------|
| **PARP Inhibitors** (olaparib, niraparib) | â­â­â­ HIGHEST | Synthetic lethality with BER deficiency |
| **Platinum** (carboplatin) | â­â­â­ HIGHEST | DNA crosslinks can't be repaired |
| **ATR Inhibitors** (berzosertib) | â­â­ High | Exploit checkpoint bypass |
| **WEE1 Inhibitors** (adavosertib) | â­â­ High | Exploit G2/M bypass |
| **Checkpoint Inhibitors** (if MSI-H) | â­ Moderate | May be eligible if TMB/MSI elevated |

### Clinical Trial Keywords

Based on Ayesha's profile (MBD4 + TP53 + HGSOC):
- "DNA repair deficiency ovarian cancer"
- "PARP inhibitor combination trial"
- "ATR inhibitor ovarian cancer"
- "MBD4 mutation basket trial"
- "BER deficiency synthetic lethal"
- "TP53 mutant ovarian cancer"

---

## ğŸ”´ WHAT OUR SYSTEM CAN DO FOR AYESHA

### Based on MBD4 + TP53 Profile:

| Our Capability | Ayesha's Situation | Action |
|----------------|-------------------|--------|
| **Toxicity â†’ Nutrition** | Carboplatin + MBD4 = DNA repair stress | NAC 600mg post-infusion, Vitamin D â­ |
| **Resistance Prediction** | MBD4+TP53 = LOW baseline resistance | Monitor for MAPK/NF1 (no somatic data yet) |
| **PARP Recommendation** | MBD4 homozygous = HIGH PARP sensitivity | â­ STRONGLY recommend PARP maintenance |
| **Trial Matching** | Rare MBD4 + TP53 combination | Search basket trials, DNA repair trials |

### What We Still Need:

1. **CA-125 baseline** â†’ Then we can:
   - Track treatment response
   - Detect recurrence early

2. **HRD Score** â†’ Then we can:
   - Confirm HRD+ status (expected with MBD4)
   - Document for PARP eligibility

3. **MSI/TMB** â†’ Then we can:
   - Determine IO eligibility
   - May be elevated due to BER deficiency

---

## ğŸ“‹ IMMEDIATE ACTION ITEMS

### For Oncologist to Order:

```
â˜ CA-125 (STAT)
â˜ FoundationOne CDx OR Tempus xT (tumor sequencing)
â˜ HRD Score (Myriad myChoice)
â˜ MSI/dMMR testing (if not on panel)
â˜ CBC, CMP, LFTs
â˜ Nutritional assessment
```

### For Our System:

```
â˜ Await somatic results â†’ Check MAPK/NF1 for resistance risk
x Input carboplatin regimen â†’ Generate toxicity-protective nutrition
â˜ Monitor CA-125 â†’ Track treatment response
â˜ After HRD result â†’ Determine maintenance strategy
```

---

## ğŸ“Š AK'S KEY NUMBERS TO TRACK

| Biomarker | Baseline | Target | Monitoring |
|-----------|----------|--------|------------|
| CA-125 | â“ TBD | <35 U/mL | Every cycle |
| Hemoglobin | â“ | >10 g/dL | Every cycle |
| ANC | â“ | >1.5 Ã— 10â¹/L | Every cycle |
| Creatinine | â“ | <1.2 mg/dL | Every cycle |
| Albumin | â“ | >3.5 g/dL | Monthly |
| HRD Score | â“ TBD | â‰¥42 = eligible | Once |

---

## ğŸ¯ PROGNOSIS CONSIDERATIONS

| Factor | AK's Status | Prognostic Impact |
|--------|-----------------|-------------------|
| Stage | IVB | Unfavorable |
| Grade | High-grade serous | Aggressive histology |
| Germline BRCA | Negative | No germline advantage |
| Somatic BRCA/HRD | **PENDING** | Critical for treatment |
| TP53 | Mutant | Standard for HGSOC |
| Performance Status | â“ | Affects treatment tolerance |
| Debulking potential | TBD after NACT | Major prognostic factor |

---

## ğŸ“ SUMMARY

**AK has Stage IVB high-grade serous ovarian cancer with MBD4 germline mutation.**

**What we KNOW:**
- â­ **MBD4 c.1293delA HOMOZYGOUS** â†’ BER pathway deficiency
- â­ **TP53 mutant** (p53 strong staining) â†’ Checkpoint bypass
- ER+/PR-, germline BRCA1/2 negative
- Extensive carcinomatosis, bilateral pleural disease
- **This is a SYNTHETIC LETHAL combination** â†’ HIGH PARP sensitivity

**What we NEED:**
- â­ CA-125 baseline (URGENT)
- HRD score (likely HIGH due to MBD4)
- MSI/TMB (may be elevated due to BER deficiency)

**What we CAN DO:**
- âœ… **PARP inhibitor: STRONGLY RECOMMENDED** (MBD4 + TP53 = synthetic lethality)
- âœ… **Platinum: HIGH SENSITIVITY expected**
- âœ… Toxicity-protective nutrition: NAC 600mg post-carboplatin infusion
- âœ… Trial matching: DNA repair deficiency basket trials
- âœ… Resistance monitoring: Watch for MAPK/NF1 mutations

**Key Message:** AK's MBD4 + TP53 combination is **RARE** but creates a **HIGHLY FAVORABLE** molecular profile for PARP inhibitors. This should be prioritized in maintenance therapy.

---

**Document Status:** Living document - update as results come in

**Next Review:** After CA-125 baseline and HRD score

---

## ğŸ“Š AK'S MOAT PROFILE

Based on our validated capabilities and the molecular profile:

| MOAT | AK's Status | Recommendation |
|------|-----------------|----------------|
| **Toxicity â†’ Nutrition** | Carboplatin + MBD4 (BER deficiency) | NAC 600mg post-infusion (DNA repair support) |
| **Resistance Prediction** | MBD4+TP53 = low baseline risk | MAPK/NF1 not detected (pending somatic) |
| **PARP Eligibility** | MBD4 + TP53 = â­ HIGHEST PRIORITY | Olaparib or Niraparib maintenance |

**The Bottom Line:** Ayesha's genetic profile makes her an **IDEAL candidate** for PARP inhibitor maintenance therapy. The MBD4 + TP53 "double hit" creates synthetic lethality that PARP inhibitors can exploit.

---

## ğŸ“š EVIDENCE & REFERENCES

### MBD4 Loss of Function â†’ BER Deficiency
1. **Sanders MA et al.** "MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML." Blood. 2018;132(14):1526-1533. DOI: [10.1182/blood-2018-03-839209](https://doi.org/10.1182/blood-2018-03-839209)
2. **Palles C et al.** "Germline MBD4 deficiency causes a multi-tumor predisposition syndrome." Am J Hum Genet. 2022;109(5):953-960. DOI: [10.1016/j.ajhg.2022.03.018](https://doi.org/10.1016/j.ajhg.2022.03.018)

### p53 Immunohistochemistry Interpretation
3. **Cole AJ et al.** "Assessing mutant p53 in primary high-grade serous ovarian carcinoma using immunohistochemistry and massively parallel sequencing." Mod Pathol. 2016;29(7):764-773. DOI: [10.1038/modpathol.2016.72](https://doi.org/10.1038/modpathol.2016.72)

### Synthetic Lethality & PARP Inhibitors
4. **Lord CJ, Ashworth A.** "PARP inhibitors: Synthetic lethality in the clinic." Science. 2017;355(6330):1152-1158. DOI: [10.1126/science.aam7344](https://doi.org/10.1126/science.aam7344)
5. **PiliÃ© PG et al.** "PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers." Clin Cancer Res. 2019;25(13):3759-3771. DOI: [10.1158/1078-0432.CCR-18-0968](https://doi.org/10.1158/1078-0432.CCR-18-0968)

### Platinum Sensitivity in DNA Repair Deficient Tumors
6. **Kelland L.** "The resurgence of platinum-based cancer chemotherapy." Nat Rev Cancer. 2007;7(8):573-584. DOI: [10.1038/nrc2167](https://doi.org/10.1038/nrc2167)

### NAC for DNA Repair Support
7. **De Flora S et al.** "Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points." Carcinogenesis. 2001;22(7):999-1013. DOI: [10.1093/carcin/22.7.999](https://doi.org/10.1093/carcin/22.7.999)

### Variant Source
8. **Ambry Genetics Lab Report** - CancerNext Expanded + RNAInsight Panel (77 genes). Order #1111986315. Result: MBD4 c.1293delA (p.K431Nfs*54) HOMOZYGOUS.

---

**Note on HRD/MSI:** MBD4 is a BER gene, not HR or MMR. HRD and MSI testing is still recommended because BER deficiency can cause secondary genomic instability. TMB is a better marker for MBD4-related hypermutation (C>T signature at CpG sites).

